Fogorvosi szemle, 2007 (100. évfolyam, 1-6. szám)

2007-06-01 / 3. szám

102

FOGORVOSI SZEMLE

100. évf. 3. sz. 2007.

Vizsgálataink alapján a DM2 prognosztikai faktornak tekinthető a gingiva carcinomás esetekben, mely kedvezőtlen, rapid lefolyásra utal.

Mivel a szöveti reakciók pathomechanizmusának egyes részletei még nem ismertek sem a diabetes mellitusban, sem pedig a daganatok terjedésében, az összefüggések pontos tisztázása további kutatómunkát igényel.

Irodalom

1. Adami HO, Chow WH, Nyren O: Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472-1477.

2. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.

3. Bettendorf O, Piffkó J, Bánkfalvi Á: Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 2004; 40: 110-119.

4. Bhawal UK, Ozaki Y, Nishimura M: Association of expression of receptor for advanced glycation end products and invasive activity of oral squamous cell carcinoma. Oncology 2005; 69: 246-255.

5. Bloomgarden ZT: Definition of the insulin resistance syndrome: The 1st World Congress on the Insulin Resistance Syndroma. Diab Care 2004; 27: 824-830.

6. Boros LG, Cascante M, Lee W-NP: Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov Today 2002; 7: 18-26.

7. Brennan PA, Mackenzie N, Quintero M: Hypoxia-inducible factor 1 alpha in oral cancer. J Oral Pathol Med 2005; 34: 385-389.

8. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-1270.

9. Clark AM, Raine K, Raphael D: The American Cancer Society, American Diabetes Association and American Heart Association joint statement on preventing cancer, cardiovascular disease and diabetes: Where are the social determinants? Diabetes Care 2004; 27: 3024.

10. Fang FM, Leung SW, Huang CC: Combined-modality therapy for squamous carcinoma of the buccal mucosa: treatment results and prognostic factors. Head Neck 1997; 19: 506-512.

11. Halmos T, Jermendy G: Diabetes mellitus, elmélet és klinikum. Medicina, Budapest 2002; 55-69.

12. HalmosT, Kautzky I, Suba I: Metabolicus syndroma. Medicina Budapest 2005; 201-204.

13. Hammarsten J, Hogstedt B: Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887-2895.

14. Hu FB, Manson JE, Liu S: Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999; 91: 542-547.

15. Kademani D, Bell RB, Bagheri S, Holmgren E, Dierks E, Potter B et al: Prognostic factors in intraoral squamous cell carcinoma: The influence of histologic grade. J Oral Maxillofac Surg 2005; 11:1599- 1605.

16. Kunkel M, Reichert TE, Benz P: Overexpression of Glut-1 and increased metabolism in tumors are associated with poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003; 97: 1015-1024.

17. Lindblad P, Chow WH, Chan J: The role of diabetes mellitus in the etiology of renal cell cancer. Diabetologica 1999; 42: 107-112.

18. Lorenzi M: Glucose toxicity in the vascular complications of diabetes: the cellular perspective. Diab Metab Rev 1992; 8: 85-103.

19. All JL, Tuckey JA, Parry BRL: Serum tumor necrosis factor alfa and insulin resistance in gastrointestinal cancer. BrJ Surg 1992; 79: 1361-1363.

20. Németh Z, Velich N, Szabó G, Suba Z: Prognosztikai faktorok jelentősége szájüregi laphámrákok esetében. Orv Hetilap 2004; 13: 661-666.

21. Neville BW, Day TA: Oral cancer and precancerous lesions. CA Cancer J Clin 2002; 52: 195-215.

22. Oliver RJ, Woodwards RT, Sloan P: Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Transplantational Research Fund studies. Eur J Cancer 2004; 40: 503-507.

23. Richardson LC, Pollack LA: Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005; 2: 48-53.

24. Riu L, Aguirre V, Kim JK: lnsulin/IGF-1 and TNF-alpha stimulates phosphorylation of IRS-1 at inhibitory Ser 307 via distinct pathways. JClin Invest 2001; 107: 181-189.

25. Salahudeen AK, Kanji V, Reckelhoff JF: Pathogenesis of diabetic -nephropathy: a radical approach. Nephrol Dial Transpl 1997; 12: 664-668.

26. Schmidt AM, Hori O, Cao R: RAGE-a novel cellular receptor for advanced glycation end products. Diabetes 1996; 45: 77-80.

27. Suba Z, Ujpál M: Az inzulinrezisztencia és a daganat összefüggései. Magyar Onkot 2006; 50: 127-135.

28. Ujpál M, Matos O, Bibok Gy: Diabetes and Oral tumors in Hungary: Epidemiological correlations. Diab Care 2004; 27: 770-774.

29. Yamamoto E, Miyakawa A, Kohama G: Mode of invasion and lymph node metastases in squamous cell carcinoma of the oral cavity. Head Neck Surg 1994; 6: 938-947.

Dr. Ujpál M, Dr. Barabás J, Dr. Szabó G, Dr. Bogdán S, Dr. Lőrincz Á, Dr. Suba Zs:

Prognostic value of type 2 diabetes among gingival cancer patients treated with surgery and irradiation

Type 2 diabetes may be regarded as a risk factor for cancers in different sites. The aim of this study was to compare the progression of primary gingival cancers in type 2 diabetic and non-diabetic patients.

This retrospective follow-up study involved 48 diabetic and 52 non-diabetic control patients with gingival squamous cell carcinoma in stage T2-3N0M0. Their treatment comprised surgical tumor extirpation, block resection of the mandible, functional cervical dissection and 60 Gy adjuvant irradiation. Progression data was recorded after a 2-year period of clinical follow-up. Surgical samples were assessed histopathologically from the aspect of tumor spread.

At the end of a 2-year follow-up period, there were significantly worse clinical results in the diabetic group concerning the cervical lymph node metastases (P<0.05) and the rate of deaths (P<0.001 ). Histologically, the degree of tumor invasion was significantly different in the diabetic group compared to the controls (P<0.01).

Type 2 diabetes can be regarded as a possible prognostic factor in cases of gingival carcinoma, forecasting an unfavorable course.

Key words: gingival carcinoma, diabetes mellitus, tumor progression, prognostic factors